Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford and Cornell University, is partnering with infectious disease modellers and public health experts from over 40 countries in Africa, Asia and America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

COVID-19 is continuing to spread across the world at a rapid rate. By 30 April 2020, the pandemic had affected at least 185 countries/regions, with more than 4 million confirmed cases and in excess of 200,000 deaths globally. The pandemic has presented a myriad of challenges for health care systems around the world, including pressures on health care staff, general hospital beds, intensive care capacity and specialized equipment. In addition to the health effects of the disease, lockdown measures to contain the disease have placed a significant economic burden on countries and communities. Policymakers must balance curtailing the negative health effects of the pandemic against minimizing the economic impact on societies, calibrating these decisions for the epidemiological, social, cultural and infrastructure context of an individual country. There is currently no treatment or vaccine for COVID-19, so countries that choose to try to interrupt its spread must rely on non-pharmaceutical interventions (NPIs); these NPIs fall into various categories of behaviour change, including self-isolation for symptomatic individuals, increased hand hygiene, and physical distancing in social settings.

The COVID-19 International Modelling Consortium (CoMo Consortium) was created by researchers at the University of Oxford together with academic colleagues at Cornell University and is partnering with infectious disease modellers and other public health experts from more than 40 countries across Africa, Asia, and South and North America. The CoMo Consortium uses a participatory approach to provide decision-making support to policymakers, using evidence from epidemiological and economic models adapted to each country’s context.

Read more on the Centre for Tropical Medicine & Global Health website

Similar stories

Ancient gene mutation found to cause rare hereditary condition

General Research

UK scientists have found that a 7,000-year-old genetic mutation is responsible for a rare form of hereditary motor neuropathy (HMN).

National consortium to study threats of new SARS-CoV-2 variants

Coronavirus COVID-19 General Research

A new national research project to study the effects of emerging mutations in SARS-CoV-2 will be launched with £2.5 million funding from UK Research and Innovation (UKRI).

Retirement of Professor Peter Brown

General

This month sees the retirement of Professor Peter Brown as Director of the Medical Research Council Brain Network Dynamics Unit at the University of Oxford.

Immunology preprint reviews launched in Nature Reviews Immunology

General Research

The Oxford-Mount Sinai (OxMS) Preprint Journal Club has partnered with Nature Reviews Immunology to launch a monthly Preprint Watch column.

No limit to the benefits of exercise in reducing the risk of cardiovascular disease

General Research

A new study led by the University of Oxford on over 90,000 participants shows that there is no upper threshold to the benefits of exercise in reducing the risk of cardiovascular disease – ‘every move counts towards better cardiovascular health.’

Accurate predictions of ovarian cancer outcome possible with new classification system

General Research

The new, Oxford-developed method for subtyping ovarian cancer has been validated in a recent collaboration between the University of Oxford and Imperial College London. Dubbed the ‘Oxford Classic’, researchers have demonstrated that it enables the accurate prediction of patient disease outcome, as well as the development of new targeted cancer therapies.